QZQing-Hua Zhong

Qing-Hua Zhong

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Qing-Hua Zhong has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Qian-Qiu Zhu

    Department of Cardiology, Yijishan Hospital of Wannan Medical College, Wuhu, China

    2 shared publications
  • Sheng-Xing Tang

    Department of Cardiology, Yijishan Hospital of Wannan Medical College, Wuhu, China

    2 shared publications
  • Yan Sun

    Department of Cardiology, Longgang Central Hospital of Shenzhen, Shenzhen, China

    2 shared publications
  • Jia-Kang He

    Department of Cardiology, First Affiliated Hospital of Dalian Medical University, Dalian, China

    1 shared publication
  • Xiao Han

    Institute of Cardio-Cerebrovascular Medicine, Central Hospital of Dalian University of Technology, Dalian, China

    1 shared publication
  • Xiao Han

    Institute of Cardio-Cerebrovascular Medicine, Central Hospital of Dalian University of Technology, Dalian, China

    1 shared publication

Latest Publications

  • 4-Hydroxychalcone alleviated Angiotensin II-induced atrial fibrillation via immunoproteasome-IKK-NF-κB signaling pathway modulation

    by Yun-Long Zhang, Ze-Yan Xu, Yan Sun, Qian-Qiu Zhu, Sheng-Xing Tang, Qing-Hua Zhong, Xiao Han

    Atrial Fibrillation (AF) is the most common type of cardiac arrhythmia and a significant contributor to stroke occurrence. Although 4-Hydroxychalcone (4HCH


  • Open Access

    4-Hydroxychalcone attenuates AngII-induced cardiac remodeling and dysfunction via regulating PI3K/AKT pathway

    by Xiao Han, Qian-Qiu Zhu, Zhi Li, Jia-Kang He, Yan Sun, Qing-Hua Zhong, Sheng-Xing Tang, Yun-Long Zhang

    Cardiac remodeling encompasses structural alterations such as hypertrophy, fibrosis, and dilatation, alongside numerous cellular and molecular functional aberrations, constituting a pivotal process in the advancement of heart failure (HF). 4-Hydroxychalcone (4-HCH) is a class of naturally occurring compounds with variable phenolic structures, and has demonstrated the preventive efficacy in hyperaldosteronism, inflammation and renal injury. However, the role of 4-HCH in the regulation of cardiac remodeling remains uncertain. A cardiac remodeling model was established in male C57BL/6 J mice via subcutaneous Ang II (1000 or 300 ng/kg/min) for 2 weeks. Mice were treated with 4-HCH (20 or 40 mg/kg/day) or vehicle control. Systolic blood pressure (SBP) was measured using a tail-cuff method, and echocardiography assessed cardiac function. Histopathological staining evaluated cardiomyocyte hypertrophy, fibrosis, inflammation, and superoxide production. Network pharmacology analysis identified potential core targets and pathways mediating the effects of 4-HCH. Expression of inflammatory cytokines and proteins related to hypertrophy, fibrosis, inflammation, and oxidative stress was assessed by quantitative real-time PCR (qPCR) and Western blotting. Our results indicated that 4-HCH significantly ameliorated Ang II-induced hypertension, cardiomyocyte hypertrophy, fibroblast activation, fibrosis, inflammation, superoxide production, and cardiac function. Network pharmacology analysis identified the PI3K-AKT pathway as a crucial mechanism underlying the effects of 4-HCH, with experimental verification demonstrating that it inhibits cardiac remodeling by downregulating this pathway and its downstream effectors, including mTOR/ERK, TGF-β/Smad2/3, NF-κB, and NOX1 independent of its blood pressure-lowering effects. These results reveal for the first time that 4-HCH alleviates cardiac remodeling, emphasizing its potential as a therapeutic agent for HF.